Masimo Archives - Page 5 of 7 - Medical Design Sourcing

Investors may have overreacted over Masimo

[Image from Pixabay]The Street appears to be reassessing its reaction to Masimo’s plans to spend $1.025 billion to acquire Viper Holdings, the parent company of Sound United.

The news of the acquisition plans on the evening Feb. 15 caused the patient monitoring tech company’s stock to lose a third of its value the next day. While MASI shares are still down more than 29% over the past five days on the Nasdaq as of this morning, the company’s stock has recovered a bit since the initial fall.

Analysts appear to be gaining more perspective over Masimo’s plans to acquire the company behind high-end sound system brands including Bowers & Wilkins, Denon, Polk Audio and Marantz.

“While we understand investors’ consternation over the Sound United deal, we believe that the sell-off was overdone and note that we expect the deal to be highly accretive to EPS, and we believe that investors get a free call option on MASI’s co…

Masimo stock falls as The Street ponders $1B Sound United acquisition

Masimo (Nasdaq: MASI) stock lost nearly a third of its value the morning after the company said it would spend $1.025 billion to acquire Viper Holdings, the parent company of Sound United.

Sound United is behind consumer tech brands including Bowers & Wilkins, Denon, Polk Audio and Marantz, making high-end sound and home theater systems. Think sophisticated speaker systems.

“We see significant opportunities to cross-leverage technologies, bringing Masimo’s clinically superior solutions into the home and on-the-go as well as bringing Sound United’s premium technologies into the hospital to advance our hospital automation connectivity and cloud-based technologies,” Masimo CEO Joe Kiani said in a news release.

“The technology and expertise within Sound United will serve us well as we aim to augment our Masimo SafetyNet strategy.”

The BTIG analysts note on the deal had the headline “MASI’s consumer tech acquisit…

How medtech fared in the first waves of the pandemic

[Photo by Martin Sanchez on Unsplash]Medtech industry revenue, research spending and employment declined in the first year of the COVID-19 pandemic, according to a Medical Design & Outsourcing analysis of financial data.

Total sales, R&D spending and employment for the world’s largest medical device companies declined in 2020 and early 2021, according to a Medical Design & Outsourcing analysis tallying the ongoing pandemic’s initial toll on the industry.

To compare performance before and during the pandemic, MDO used the financial data that we’ve historically gathered to rank our Big 100 companies in the last three years. The majority of these companies reported full-year results for 2020; others operate on a fiscal year and reported annual results in the first half of 2021.

Some companies are not in this year’s Big 100 but were included in the analysis because they were ranked in pre-pandemic years. The handful of companies that joined this yea…

How medtech fared in the first waves of the pandemic

[Photo by Martin Sanchez on Unsplash]

Medtech industry revenue, research spending and employment declined in the first year of the COVID-19 pandemic, according to a Medical Design & Outsourcing analysis of financial data.

Total sales, R&D spending and employment for the world’s largest medical device companies declined in 2020 and early 2021, according to a Medical Design & Outsourcing analysis tallying the ongoing pandemic’s initial toll on the industry.

To compare performance before and during the pandemic, MDO used the financial data that we’ve historically gathered to rank our Big 100 companies in the last three years. The majority of these companies reported full-year results for 2020; others operate on a fiscal year and reported annual results in the first half of 2021.

Some companies are not in this year’s Big 100 but were included in the analysis because they were ranked in pre…

Masimo seeks to boost automation of newborn screenings in Europe

[Image from Masimo]Masimo (NSDQ:MASI) announced earlier this week that it launched a new patient monitoring and connectivity hub.

The first application of Dual SET Oximetry for Root offers a significant advancement to the company’s Masimo SET-guided critical congenital heart disease (CCHD) screening, according to a news release. Masimo will combine the platform with the CE-marked Masimo SET MOC-9 module and the Eve CCHD newborn screening application for Root to enhance the automation of newborn screenings using Dual SET Oximetry.

Get the full story at our sister site, Medical Design & Outsourcing.

Masimo seeks to boost automation of newborn screenings in Europe

[Image from Masimo]

Masimo (NSDQ:MASI) announced earlier this week that it launched a new patient monitoring and connectivity hub.

The first application of Dual SET Oximetry for Root offers a significant advancement to the company’s Masimo SET-guided critical congenital heart disease (CCHD) screening, according to a news release. Masimo will combine the platform with the CE-marked Masimo SET MOC-9 module and the Eve CCHD newborn screening application for Root to enhance the automation of newborn screenings using Dual SET Oximetry.

Masimo designed its Eve CCHD newborn screening application to simplify the CCHD screening process through step-by-step visual instructions, animations and a detailed display of screening results. The company said this offers standardized and enhanced clinical workflows, improved consistency and the potential to reduce calculation errors.

Additionally, Masimo touts …

Masimo beats the street in Q3 results

Masimo (NSDQ:MASI) this week posted third-quarter results that beat the overall consensus forecast on Wall Street.

The Irvine, California-based monitoring technology company reported profits of $57.8 million, or $1.00 per share, on sales of $307.4 million, for the three months ended October 2, for a bottom-line gain of 17% on sales growth of 10.5% compared with Q3 2020.

Adjusted to exclude one-time items, earnings per share were 94¢, 3¢ ahead of The Street, where analysts were looking for sales of $295.8 million.

“In the wake of the pandemic and its ongoing challenges, we have continued to demonstrate the commitment and responsiveness required to meet the needs of clinicians and patients around the world. We are happy to report double-digit revenue growth and EPS growth that exceeded expectations for the third quarter,” CEO Joe Kiani said.

Masimo adjusted its full-year revenue estimates from $1.216 billion to $1.230 billion.

Shares in…

Masimo officials think their tech could reduce healthcare worker burnout

[Image from Masimo]Masimo (NSDQ:MASI) announced today that University Hospitals (UH) of Cleveland is using its Masimo Patient SafetyNet system.

Irvine, California-based Masimo’s Patient SafetyNet remote monitoring and supplemental alarm system was selected to combat nurse burnout by improving workflows and reducing workloads, according to a news release.

Such burnout has been a topic of interest amid the latest surge of COVID-19, with top officials from Medtronic (NYSE:MDT), Johnson & Johnson (NYSE:JNJ), NuVasive (NASDAQ: NUVA) and Zimmer Biomet Holdings (NYSE:ZBH) recently warning investors of the problem.

Patient SafetyNet displays real-time information from connected Masimo and third-party devices at central stations and on remote smart devices using Replica, offering clinicians a way to keep track of up to 200 patients per view station at a time. The platform allows actionable alarms and alerts to be sent directly to clinicians,r regardless of…

Masimo beats The Street in Q2 amid elective surgeries rebound

Masimo (NASDAQ:MASI) posted second-quarter results that beat the consensus forecast on Wall Street, with the patient monitoring tech company upping its 2021 guidance.

The Irvine, Calif.–based company yesterday evening reported profits of $50.2 million, or 88¢ per share, on sales of $305.1 million for the three months ended July 3, 2021, for a bottom-line slide of nearly –10% on sales growth of 1.4% compared with Q2 2020.

Adjusted to exclude one-time items, earnings per share were 94¢, 4¢ ahead of The Street, where analysts were looking EPS of 90¢ on sales of $295.6 million.

“We are happy to report strong second-quarter results,” Masimo CEO Joe Kiani said in a news release.

“While we expected the drivers and capital orders of 2021 to be lower than we achieved in 2020 due to high demand during the height of COVID-19, and expected sensor volumes to rebound as elective surgeries recover, we did not anticipate the very strong increase in si…

FDA clears Masimo wearable thermometer for prescription, OTC use

[Image from Masimo]Masimo (NSDQ:MASI) announced today that it received FDA 510(k) clearance for two uses of its Radius Tº wearable thermometer.

Irvine, Calif.-based Masimo clearances for Radius Tº cover both prescription use and over-the-counter use for patients and consumers five years of age and older, according to a news release.

Radius Tº includes continuously trending temperature measurements and Bluetooth connectivity for automating remote, continuous body temperature status through a paired connection to a Masimo patient monitoring or telehealth solution in patients. Consumers track temperature status through the Radius Tº smartphone application.

For prescription use, Radius Tº is compatible with the Root patient monitoring and connectivity hub and the Rad-97 patient monitor. It can also be paired with the Masimo SafetyNet app for remote patient management from the home or other care locations.

It offers streamlined workflows, convenient weara…

Masimo dips after hours despite Street-beating Q1, raised guidance

Masimo (NSDQ:MASI) shares dipped after hours today despite first-quarter results that topped the consensus forecast.

The Irvine, Calif.-based company posted profits of $53.4 million, or 92¢ per share, on sales of $299 million for the three months ended April 3, 2021, for a -17.2% bottom-line slide on sales growth of 10.9%.

Adjusted to exclude one-time items, earnings per share were 90¢, 2¢ ahead of Wall Street, where analysts were looking for sales of $295.2 million.

“Our first quarter results illustrate the resiliency of our customers and our business. Following a year in 2020 where we achieved over 20% revenue growth and shipped over two times the usual number of drivers due to the rise of the COVID pandemic, we delivered double-digit revenue growth and driver shipments that exceeded expectations in the first quarter,” Masimo chairman & CEO Joe Kiani said in a news release. “We are happy to see signs of the pandemic receding in most sta…

UCLA prof: Racial bias in medical devices based in physics

(Image from the American Lung Association)

The laws of physics may be making medical devices biased against people of color, according to a UCLA engineering professor.

Achuta Kadambi, an assistant professor at the UCLA Samueli School of Engineering, published a column in the journal Science about how dataset representation is not the only factor leading to bias in medtech.

Kadambi described how the inherent physics behind medical devices could vary across race and gender, citing several examples of potential physics-based bias.

Get the full story on our sister site, Medical Design & Outsourcing.